Regent Investment Management LLC boosted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 63.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,456 shares of the medical instruments supplier’s stock after buying an additional 2,119 shares during the quarter. Regent Investment Management LLC’s holdings in Becton Dickinson and were worth $1,375,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Harvest Group Wealth Management LLC acquired a new position in Becton Dickinson and during the first quarter worth about $25,000. Hexavest Inc. acquired a new position in Becton Dickinson and during the second quarter worth about $28,000. Pinnacle Financial Partners Inc. acquired a new position in Becton Dickinson and during the first quarter worth about $29,000. RPG Investment Advisory LLC acquired a new position in Becton Dickinson and during the first quarter worth about $32,000. Finally, Aspire Private Capital LLC acquired a new position in Becton Dickinson and during the fourth quarter worth about $39,000. Institutional investors own 84.80% of the company’s stock.

Shares of BDX traded up $0.62 on Monday, hitting $255.01. 16,368 shares of the stock traded hands, compared to its average volume of 738,215. The company has a quick ratio of 0.59, a current ratio of 0.96 and a debt-to-equity ratio of 0.82. The stock has a market cap of $68.62 billion, a price-to-earnings ratio of 23.15, a P/E/G ratio of 1.88 and a beta of 1.12. The firm has a 50 day moving average price of $247.96. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. The business had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The company’s quarterly revenue was down .6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.65 earnings per share. On average, sell-side analysts expect that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 1.21%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s payout ratio is 27.97%.

BDX has been the topic of several recent research reports. KeyCorp upped their price target on shares of Harsco from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Friday, May 10th. Wells Fargo & Co reduced their price target on shares of Nevro from $75.00 to $70.00 and set an “outperform” rating on the stock in a report on Monday, May 13th. Zacks Investment Research downgraded shares of GreenTree Hospitality Group from a “buy” rating to a “hold” rating in a report on Monday, May 20th. Barclays downgraded shares of Buckeye Partners from an “overweight” rating to an “equal weight” rating in a report on Monday, May 13th. Finally, Morgan Stanley reduced their price target on shares of Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating on the stock in a report on Tuesday, July 16th. Five research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $263.58.

In other Becton Dickinson and news, EVP Betty D. Larson sold 1,700 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $224.97, for a total transaction of $382,449.00. Following the transaction, the executive vice president now owns 11,493 shares of the company’s stock, valued at $2,585,580.21. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Samrat S. Khichi sold 16,085 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the transaction, the executive vice president now directly owns 12,608 shares in the company, valued at approximately $2,958,845.44. The disclosure for this sale can be found here. Insiders have sold 21,154 shares of company stock worth $4,955,775 in the last three months. Insiders own 0.12% of the company’s stock.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Options Trading

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.